U.S. C-Arms Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: U.S. C-Arms Market
- ✓Market Size 2024: USD 1.12 billion
- ✓Market Size 2032: USD 1.71 billion
- ✓CAGR: 5.4%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Lock compliant contracts now: ASC operators and hospital capital committees should require vendors to supply Section 524B cybersecurity documentation and QMSR-aligned quality records before signing any 2026 contract. These requirements now govern premarket submissions, so unverified equipment risks delays and recall exposure.
C-Arms in the United States: Market Overview
The United States accounts for roughly 40% of global C-arm demand, valued at USD 1.12 billion in 2024 across hospitals, ambulatory surgical centers and specialty clinics. Demand is concentrated in full-size mobile units used in operating rooms and cath labs, while mini C-arms serve orthopaedic and hand surgery. Premarket clearance by the FDA's Center for Devices and Radiological Health gates every product entry, and Medicare reimbursement rules determine which procedures justify capital spending.
Private manufacturers have led product development, with GE HealthCare, Siemens Healthineers and Philips holding most hospital installations through direct sales and service contracts. Government's role is regulatory rather than purchasing: the Department of Veterans Affairs and Defense Health Agency buy through federal supply schedules, but they represent a small share of volume. Policy has shaped the market's form mainly through radiation dose standards in 21 CFR 1020.32 and reimbursement architecture, not through public ownership.
Policy-Driven Growth in US C-Arms
The CY2026 Outpatient Prospective Payment System final rule from the Centers for Medicare and Medicaid Services begins phasing out the Medicare inpatient-only list, moving orthopaedic and spine procedures into outpatient settings. Every C-arm used in these cases is reimbursed through the procedure's ambulatory payment classification, so hospitals and ASCs buy imaging capacity to protect margin. Public Law 119-21, the One Big Beautiful Bill Act of July 2025, also created a USD 50 billion Rural Health Transformation Program for FY2026–2030, administered by CMS, which states can direct toward equipment.
The Veterans MISSION Act of 2018 (Public Law 115-182) expanded community care, routing veterans' surgical cases to private ASCs that must meet VA quality standards, and those ASCs install C-arms to win contracts. The translation to growth is direct: each reimbursement shift or program grant converts into a capital purchase order, typically full-size mobile units for hospitals and mini C-arms for ASCs. Demand therefore follows payment architecture as much as clinical guidelines.
Regulatory Barriers and Compliance Costs
Every C-arm sold in the United States requires a 510(k) premarket notification under Section 510(k) of the Federal Food, Drug, and Cosmetic Act, classified under 21 CFR 892.1650 for image-intensified fluoroscopic systems. FDA's Center for Devices and Radiological Health administers review against MDUFA V performance goals, but a standard 510(k) fee above USD 20,000 and review cycles of three to six months add cost for smaller entrants. Section 524B of the same Act, effective March 29, 2023, requires cybersecurity documentation including a software bill of materials, which mini C-arm makers without in-house security teams struggle to produce.
Radiation performance is enforced under 21 CFR 1020.32, which sets fluoroscopic dose and leakage limits, and states separately register and inspect installations under the Radiation Control for Health and Safety Act of 1968. Trade policy adds cost: the Department of Commerce opened a Section 232 investigation into imports of medical devices in September 2025, and any resulting duties land on C-arms built in Germany and Japan. Federal buyers are further constrained by the Trade Agreements Act, which limits VA and Defense purchases to designated countries.
Policy-Created Opportunities in the United States
The Rural Health Transformation Program, created under Public Law 119-21 with USD 50 billion across FY2026–2030, funds state-directed purchases of diagnostic and surgical imaging by rural hospitals. Mobile full-size C-arms from GE HealthCare's OEC line and Siemens Healthineers' Cios family suit critical access hospitals, which lack fixed suites. State programmes funded through CMS allocations give vendors with established US service networks a practical advantage over importers.
Ambulatory surgical centers form the second opportunity. The CY2026 OPPS inpatient-only list phase-out and annual Covered Procedures List expansions move spine and orthopaedic cases into ASCs, which require mini C-arms and compact flat-panel systems. A third opportunity sits in regulatory incentives: AI dose-reduction software for fluoroscopy can qualify for FDA's Breakthrough Devices Program under Section 515B of the FD&C Act, and such products qualify for CMS's Transitional Coverage for Emerging Technologies pathway.
Market at a Glance
| Indicator | Detail |
|---|---|
| Market Size 2024 | USD 1.12 billion |
| Market Size 2032 | USD 1.71 billion |
| Growth Rate (CAGR) | 5.4% |
| Most Critical Decision Factor | Reimbursement alignment with CMS hospital outpatient payment rules |
| Largest Region | Southern United States |
| Competitive Structure | Consolidated oligopoly led by three multinationals |
Leading Market Participants
- GE HealthCare
- Siemens Healthineers
- Philips
- Canon Medical Systems USA
- Ziehm Imaging
- Shimadzu Medical Systems USA
- Fujifilm Healthcare Americas
- Medtronic
- Stryker
- Orthoscan
Regulatory and Policy Environment
The centrepiece is the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), administered by FDA's Center for Devices and Radiological Health. C-arms clear as Class II devices through 510(k) under 21 CFR 892.1650, and the Quality Management System Regulation amending 21 CFR Part 820 takes effect on February 2, 2026, aligning US requirements with ISO 13485:2016. Manufacturers must also meet 21 CFR 1020.32 radiation limits and Section 524B cybersecurity rules, while ASCs operate under Medicare conditions in 42 CFR Part 416.
Upcoming changes include MDUFA VI reauthorisation ahead of the September 30, 2027 expiry of MDUFA V, and continued FDA guidance on AI-enabled device software functions. Against regional peers, the US 510(k) route is faster and less costly than Canada's device licence regime under the Medical Devices Regulations (SOR/98-282), and it avoids the notified body certification required under the EU MDR, Regulation (EU) 2017/745, which lengthens timelines for C-arms sold in Europe.
Long-Term Policy Outlook for US C-Arms
By 2032, the most consequential policy change will be the completed phase-out of the Medicare inpatient-only list, which the CY2026 OPPS rule schedules across three years, moving most elective orthopaedic and spine procedures into ASCs. This shifts capital demand toward compact C-arms and service contracts, pushing the market from USD 1.12 billion in 2024 toward USD 1.71 billion by 2032 at a 5.4% CAGR. Hospital outpatient departments will also consolidate imaging suites, favouring vendors with cloud-enabled dose monitoring.
Section 232 duties will determine whether import-dependent suppliers relocate assembly to US facilities. FDA's AI-enabled device software guidance will set the evidence standard for dose-reduction features, and MDUFA VI will define review performance goals from FY2028. The Rural Health Transformation Program's later tranches for FY2028–2030 will keep funding state-directed equipment purchases in rural hospitals.
Frequently Asked Questions
Market Segmentation
- Full-Size Mobile C-Arms
- Mini C-Arms
- Fixed Ceiling-Mounted C-Arms
- Hybrid Surgical C-Arms
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
- Veterans Affairs Facilities
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.